Browse the corpus

Dystonia is a hyperkinetic movement disorder characterized by sustained or intermittent, repetitive, patterned, tremulous, or jerky movements affecting the extremities, face, neck, trunk, pelvis, or larynx. This course details acute dystonic reactions that typically occur within 96 hours of exposure to or dose escalation of an offending agent, most commonly dopamine receptor blocking agents such as haloperidol, risperidone, metoclopramide, and prochlorperazine, and the underlying pathophysiology, which involves dopaminergic–cholinergic imbalance within the basal ganglia, particularly reduced D2 receptor activity leading to relative cholinergic overactivity. This activity reviews the prompt recognition, clinical evaluation, management, and associated complications of acute dystonic reactions across care settings, which may include significant distress and, rarely, life-threatening laryngeal involvement. Participants will also gain an understanding of medication reconciliation, risk stratification, airway assessment, and evidence-based treatment using anticholinergics and benzodiazepines. This activity for healthcare professionals is designed to enhance the learner's competence in identifying dystonic reactions, addressing complications, performing appropriate follow-up to reduce recurrence, and implementing an interprofessional approach to manage this condition, thereby improving patient safety and minimizing misdiagnosis. Objectives: Identify clinical features associated with acute dystonic reactions. Differentiate acute dystonia from other mimicking conditions. Select appropriate treatment strategies for patients with dystonic reactions. Collaborate with interprofessional team members to improve care coordination and outcomes for patients with dystonic reactions. Access free multiple choice questions on this topic.

Dystonia is a hyperkinetic movement disorder characterized by sustained or intermittently sustained posture or movement. These are repetitive, patterned, may be tremulous or jerky, and can involve the extremities, face, neck, abdomen, pelvis, or larynx. Acute dystonic reactions are the sudden onset of such movements that typically reach peak intensity within minutes to hours after exposure to an inciting factor.[1] In the vast majority of cases, symptom onset occurs within 96 hours of initiating or augmenting the causative agent.[2] Drug exposure remains the most common cause of acute dystonic reactions, particularly following administration of dopamine receptor blocking agents (DRBAs). Acute dystonia may also develop in association with metabolic derangements, eg, hypocalcemia or hypomagnesemia, inherited disorders, and functional neurological disorders.[3] Because no confirmatory laboratory or imaging test establishes the diagnosis, clinical evaluation guides decision-making and demands a high index of suspicion, along with careful assessment of the temporal relationship between medication exposure and symptom onset. Accurate diagnosis depends on recognizing clinical variability and excluding conditions that mimic dystonia. Anticholinergic agents and benzodiazepines serve as the primary pharmacologic therapies to reverse or reduce symptoms. Although most reactions remain self-limited and reversible, patients often experience significant discomfort, anxiety, and functional impairment. In rare cases, laryngeal dystonia develops and may progress to life-threatening airway obstruction, requiring immediate airway management and urgent intervention.

DRBAs, including antipsychotics and antiemetics, are among the most frequently described causes of acute dystonic reactions. Other medication classes, including antidepressants, anesthetics, and anticonvulsants, have also been implicated through case reports and clinical observations. Amongst the antipsychotics, the first generation (ie, "typical" antipsychotics) carry the greatest risk of inducing dystonia due to their stronger dopaminergic blocking action. These include haloperidol, perphenazine, and thioridazine, which have been historically used in the management of acute psychosis, agitation, and bipolar mania. The advent of second-generation antipsychotics (ie, "atypical" antipsychotics), eg, risperidone, quetiapine, and olanzapine, has been associated with a lower overall incidence of acute dystonic reactions. However, the risk is not eliminated, particularly at higher doses or during rapid titration. In emergency and inpatient settings, antiemetic-induced acute dystonias remain commonly encountered, especially following administration of metoclopramide and prochlorperazine. Both are widely prescribed for nausea and vomiting and share dopamine-blocking properties at the D2 receptor. Because of this risk, some clinicians coadminister diphenhydramine prophylactically when prescribing these agents.[2] Beyond DRBAs, case reports demonstrate that drugs, eg, methylphenidate, albendazole, chloroquine, rivastigmine, and foscarnet have all been implicated in cases of acute dystonic reaction.[3][4] Agents associated with dystonic reactions include: Antipsychotics First generation (typical): haloperidol, thioridazine, perphenazine Second generation (atypical): risperidone, quetiapine, olanzapine Antiemetics: metaclopramide, perchlorperazine, promethazine [5] Antiepileptics: carbamazepine, valproate, phenytoin, lamotrigine [1] Antidepressants: sertraline, fluoxetine, fluvoxamine, paroxetine [6] Anesthetic agents: propofol, sevoflurane,[7] fentanyl Neurostimulants: methylphenidate Antiparasitic agents/antimalarial: albendazole, chloroquine VMAT2 inhibitors: tetrabenazine [8] Illicit substances: cocaine

The exact incidence of acute dystonic reactions remains uncertain due to their variable clinical presentation, transient nature, and the absence of confirmatory diagnostic testing. Several risk factors have been consistently identified, including male gender, younger age, and recent cocaine use.[9][10] A prior history of a dystonic reaction is one of the strongest predictors of recurrence, and symptoms can reemerge even after reexposure to the same agent or after dose escalation of an antipsychotic medication.[11] One study reported an incidence of 10.5% and 2.2% in patients treated with first-generation and second-generation antipsychotics, respectively.[12] Antiemetic-associated dystonic reactions have also been reported, with an incidence of approximately 8.3% in adults treated with metoclopramide and 4% with prochlorperazine. In comparison, the incidence is less than 1% with other medication classes such as anticonvulsants, antidepressants, and neurostimulants.[6] Genetic factors may contribute to susceptibility to acute dystonic reactions. Variations in drug metabolism, particularly cytochrome P450 2D6 (CYP2D6) enzyme polymorphisms, have been associated with altered metabolism of dopamine receptor–blocking drugs. Individuals with CYP2D6 deficiency are at higher risk of developing dystonic reactions following exposure to agents (eg, metoclopramide).[2]

The basal ganglia comprise a network of subcortical nuclei responsible for the integration and modulation of cortical input to produce smooth, coordinated motor activity. Within this circuit, the striatum plays a central role in balancing dopaminergic and cholinergic neurotransmission. Acute dystonic reactions are believed to result from an imbalance between dopaminergic and cholinergic systems within the striatum. Blockade of dopaminergic input, particularly D2 receptor activity, reduces inhibitory signaling, leading to relative overactivity of cholinergic interneurons and subsequent hyperkinetic movement.[13] This hypothesis is supported by clinical and experimental findings demonstrating that agents with potent dopamine receptor antagonism (eg, typical antipsychotics) frequently precipitate dystonia. In contrast, drugs with intrinsic anticholinergic activity (such as clozapine and thioridazine) rarely do.[1] Further evidence of catecholaminergic dysregulation arises from studies in which healthy volunteers exposed to tyrosine hydroxylase inhibitors developed acute dystonic symptoms in approximately 20% of cases.[8] This observation suggests that reduced catecholamine synthesis, rather than simple receptor blockade, may induce compensatory cholinergic upregulation leading to dystonic movements. Age-related neurochemical changes may also influence susceptibility; the density of functional dopaminergic and cholinergic receptors declines with aging, which may help explain the higher incidence of acute drug-induced dystonic reactions among younger individuals.[14]

Acute dystonic reactions typically present within 96 hrs following an exposure to an offending agent for the first time or an increment in the dose of a previously tolerated drug. Therefore, obtaining a detailed medication history, particularly recent use or dose adjustments of DRBAs or other pertinent offending agents, is essential. Acute dystonic reactions, as opposed to chronic dystonias, can cause pain and are associated with significant anxiety. Acute dystonia can worsen when 1 or more muscle groups are activated, eg, while walking; occasionally, acute dystonia can only be visible during certain activities. Involvement of oropharyngeal musculature can lead to dysarthria, dysphagia, or dysphonia. The symptoms can range from a few seconds to several hours, and individuals with a prior history of dystonic reaction are at significantly higher risk of recurrence, even if reexposed to a different agent within the same pharmacological class.[1] Dystonic reactions are best categorized based on the anatomic distribution of muscle involvement (see Table. Dystonic Reactions). While they can affect any muscle group, they most frequently involve the head and neck, followed by the trunk and limb muscles. Table Table. Dystonic Reactions.

Evaluation of an acute dystonic reaction should begin with immediate assessment and stabilization of hemodynamic and respiratory status. Particular attention should be given to identifying signs of laryngeal involvement, as acute laryngeal dystonia can be life-threatening and may present with stridor as an early indicator of impending airway compromise. Once hemodynamic stability is ensured, a focused neurologic and systemic examination should be performed, followed by a detailed history that includes all recent medication exposures, including prescriptions, over-the-counter, or illicit substances over the preceding several days. Establishing a temporal relationship between the onset of symptoms and initiation or dose escalation of a potential offending agent is critical for diagnosis. Treatment should not be delayed when a reasonable clinical suspicion of an acute dystonic reaction exists, as prompt therapy is both diagnostic and therapeutic. Although autonomic symptoms, eg, tachycardia and hypertension, can occasionally accompany oculogyric crises, acute dystonic reactions are generally not associated with significant hemodynamic instability.[15] Drug paraphernalia or the presence of, or report of, illicit substances may raise suspicion that the patient’s drugs may have been cut or spiked with an offending agent.[16] However, in atypical presentations or when the diagnosis is uncertain, limited investigations may be considered to exclude metabolic, structural, or functional mimics.

Treatment of acute dystonic reaction centers on discontinuation of the offending agent and on balancing excessive cholinergic output to restore neurochemical balance. The most commonly available drugs in the emergency setting for the treatment of acute dystonic reactions are diphenhydramine and benztropine. Symptoms usually improve or resolve dramatically within 10 to 30 minutes of administration of parenteral anticholinergics. The half-life of most antipsychotic agents is longer than that of most diphenhydramine or benztropine, requiring redosing of anticholinergic medications. Supportive measures (eg, oxygen or assisted ventilation) should be provided immediately if indicated. First-Line Treatments Diphenhydramine is used for its anticholinergic effect and central nervous system (CNS) penetration. Intravenous administration is preferred to intramuscular administration due to its faster onset. Typical dosing for diphenhydramine is 50 mg intravenous (IV) in adults and 1 mg/kg up to 50 mg IV in pediatric patients. Once the acute dystonic reaction is treated and symptoms improve, diphenhydramine should be administered orally every 6 hours for 1 to 2 days to prevent symptom recurrence. Benztropine is another anticholinergic medication with significant CNS penetration, available in both IV and intramuscular (IM) forms, with a similar time to onset of effect. Typical dosing of benztropine is a single IV dose of 1 to 2 mg, followed by 1 to 2 mg by mouth. A short-term course of 1 to 2 mg orally twice daily for up to 7 days can be offered to prevent recurrence. Benztropine use in pediatric patients for acute dystonia is considered off-label. Second-Line Treatments Second-line therapy with IV benzodiazepines may be considered for patients who fail to respond completely to anticholinergic therapy. IV or IM lorazepam at 0.05 to 0.10 mg/kg or IV diazepam at 0.1 mg/kg may be considered. If symptoms do not improve after appropriate dosing of anticholinergic and benzodiazepine therapy after 3 treatment cycles, then clinicians should reassess the diagnosis and consider alternative etiologies, including seizures, catatonia, functional neurological disorders, or structural lesions. Monitoring and Follow-Up

Second-line therapy with IV benzodiazepines may be considered for patients who fail to respond completely to anticholinergic therapy. IV or IM lorazepam at 0.05 to 0.10 mg/kg or IV diazepam at 0.1 mg/kg may be considered. If symptoms do not improve after appropriate dosing of anticholinergic and benzodiazepine therapy after 3 treatment cycles, then clinicians should reassess the diagnosis and consider alternative etiologies, including seizures, catatonia, functional neurological disorders, or structural lesions. Monitoring and Follow-Up Patients who experience respiratory symptoms or require supplemental oxygen should be observed for 12 to 24 hours after symptom resolution to monitor for recurrence. For patients who experienced an acute dystonic reaction on antipsychotic medication, close follow-up with psychiatry should be given. If continuation of the offending agent is deemed necessary, the patient should remain on an anticholinergic medication until an agent with less potential for a dystonic reaction can be initiated.

A reliable history revealing the use of an offending agent is one way to diagnose and treat acute dystonic reactions. However, in an emergency setting, many patients, especially those with acute psychosis, and the pediatric population may not have the appropriate agency to give a reliable history regarding the exposure. In those circumstances, clinicians must rely on clues that may point towards other conditions that can appear like a drug-induced dystonia, but they are treated differently. Some of these conditions are listed below, and key points that differentiate them from drug-induced dystonic reactions are highlighted. Catatonia Catatonia is a neuropsychiatric syndrome characterized by rigidity, akinesis, waxy flexibility, negativism, and mutism, features not typically observed in acute dystonic reactions. Unlike acute dystonia, catatonia lacks the abrupt onset following drug exposure and is usually associated with mood disorders, psychosis, or medical illness. The treatment of choice for catatonia is benzodiazepines, particularly lorazepam, whereas anticholinergic agents are minimally beneficial in catatonic states.[17] Focal Seizures of Temporal Origin Seizures, especially those originating from the temporal lobe, can present with transient dystonic posturing of the upper extremity, often serving as a lateralizing sign to the contralateral hemisphere.[18] These postures are brief and episodic, frequently accompanied by head deviation, automatisms, impaired awareness, or progression to clonic movements. Electroencephalographic (EEG) correlation confirms the diagnosis, and the episodes typically respond to benzodiazepines or antiseizure medications. A distinctive example is the facio-brachial dystonic seizure seen in leucine-rich glioma-inactivated 1 (LGI1) antibody-associated encephalitis.[19] Vascular Causes Ischemic stroke, although rare, is a recognized cause of acute or delayed dystonic posturing. Lesions involving the lentiform nucleus, caudate, or posterior thalamus can produce contralateral hemidystonia or focal dystonic posturing.[20] These symptoms may emerge immediately or weeks to months after the cerebrovascular event. Neuroimaging (CT or MRI) is critical to differentiate vascular etiologies from drug-induced reactions, particularly in patients without a history of recent dopamine-blocking agent exposure. Functional Neurological Disorder

Ischemic stroke, although rare, is a recognized cause of acute or delayed dystonic posturing. Lesions involving the lentiform nucleus, caudate, or posterior thalamus can produce contralateral hemidystonia or focal dystonic posturing.[20] These symptoms may emerge immediately or weeks to months after the cerebrovascular event. Neuroimaging (CT or MRI) is critical to differentiate vascular etiologies from drug-induced reactions, particularly in patients without a history of recent dopamine-blocking agent exposure. Functional Neurological Disorder Patients with functional (psychogenic) movement disorders can present with apparent dystonia that lacks the characteristic physiological consistency of organic etiologies. Clues suggesting functional neurological disorder include distractibility, variability, and inconsistency of posturing, along with active resistance during attempted passive movement. Fixed postures and the presence of other functional neurological signs further support this diagnosis. Metabolic Derangements Hypocalcemia or hypomagnesemia may also precipitate dystonic posturing, which does not usually respond to anticholinergics. Structural Lesions Retropharyngeal abscesses can mimic cervical dystonia, often presenting with a fixed posture, significant neck pain with neck movement, and no response to anticholinergics. A CT with contrast is diagnostic for retropharyngeal abscesses.[21] Several less common conditions may mimic acute dystonic reactions, including temporomandibular joint dislocation, mandibular or orbital fractures, tetanus, and strychnine poisoning. A detailed physical examination, serum calcium evaluation, history of toxin exposure, and appropriate imaging can aid in differentiating these conditions.

The prognosis for acute dystonic reactions is generally excellent with prompt recognition and appropriate treatment, most often with anticholinergic therapy (with or without adjunctive benzodiazepines). Symptoms typically improve rapidly, often within minutes to hours after treatment, and most patients recover fully without long-term sequelae. Recurrence can occur, particularly if the offending medication is continued or reintroduced, or if anticholinergic therapy is not continued briefly after initial resolution when clinically indicated. Overall outcomes are favorable when the trigger is identified, avoided in the future, and the event is clearly documented to prevent inadvertent repeated exposure. Rarely, when the etiology of dystonic posturing is cerebrovascular or epileptic in origin, patients may be left with serious sequelae if these causes are not recognized early, particularly when other atypical signs and presenting features are overlooked. In addition, although uncommon, death may occur if life-threatening complications, such as laryngeal dystonia with stridor and resultant airway compromise, are not identified and managed promptly.

Complications associated with dystonic reactions include: Airway compromise (rare), including laryngeal dystonia or stridor and acute respiratory distress Dysphagia and aspiration risk, particularly with oropharyngeal or laryngeal involvement Severe anxiety, panic, and distress, sometimes misinterpreted as psychogenic symptoms Misdiagnosis leading to unnecessary evaluations or treatments (eg, seizure workup or stroke alerts) further delays definitive therapy Recurrent dystonia due to continued dosing or reexposure to the precipitating agent, including in urgent care or emergency settings Musculoskeletal pain, muscle spasm–related injury, or rhabdomyolysis (very uncommon, typically with prolonged severe contractions) Ocular complications (eg, corneal irritation from oculogyric crisis) Trauma and injury from abnormal posturing or sudden spasms Treatment-related adverse effects, especially anticholinergic toxicity (sedation, confusion, urinary retention) or benzodiazepine-related sedation or respiratory depression in susceptible patients

Patients should be counseled that recurrence of acute dystonic reactions is more likely with repeated exposure to the offending agent or related drugs, particularly with higher doses, rapid dose escalation, or parenteral administration. Deterrence centers on avoiding the precipitating medication when feasible, using the lowest effective dose and gradual titration when a dopamine-blocking agent is clinically necessary, and documenting the reaction in the medical record as a significant adverse drug reaction. Patients with a prior acute dystonic reaction should be instructed to proactively disclose this history to all clinicians, including urgent care and emergency clinicians, because antiemetics frequently administered in acute settings may also precipitate dystonia. Patient education should emphasize early symptom recognition and the importance of prompt evaluation, as reactions may involve the face, neck, jaw, eyes, or trunk and can be frightening despite being treatable. Patients should be advised to seek urgent care for severe symptoms, especially if there is difficulty speaking, swallowing, or breathing, and to avoid taking additional doses of the suspected trigger medication until reviewed by a clinician. Discharge counseling should include a clear plan regarding any short course of anticholinergic therapy prescribed to reduce recurrence, the expected time course of improvement, and follow-up to reassess the indication for the offending medication and to select safer alternatives when appropriate.

Acute dystonic reactions are sudden, often painful hyperkinetic movement disorders that typically occur within 96 hours of exposure to or dose escalation of dopamine receptor–blocking agents, including antipsychotics and antiemetics. Pathophysiology involves dopaminergic–cholinergic imbalance within the basal ganglia, producing patterned, repetitive contractions that may affect the face, neck, trunk, extremities, or larynx. Although many cases resolve with prompt anticholinergic therapy, delayed recognition can lead to severe distress, functional impairment, or rare airway compromise. Diagnosis remains clinical and depends on identifying the temporal relationship between medication exposure and symptom onset while excluding mimics. Enhancing outcomes requires coordinated, patient-centered care across disciplines. Physicians and advanced practitioners lead rapid assessment, airway evaluation, discontinuation of the offending agent, and initiation of anticholinergic therapy with or without benzodiazepines. Pharmacists perform detailed medication reconciliation, identify high-risk dopamine receptor–blocking drugs, and recommend safer alternatives. Nurses support early detection, continuous monitoring, and timely escalation of airway concerns while reinforcing discharge education. Ethical and safety considerations include respecting patient autonomy through transparent communication about medication risks, benefits, and alternatives, and addressing the anxiety and distress that commonly accompany these abrupt, frightening symptoms. Clear delineation of team responsibilities and reliable interprofessional communication are essential to avoid repeated exposure in acute care settings, where triggering medications may be administered quickly for agitation, nausea, or migraine. Care coordination should ensure a seamless transition from acute management to follow-up, including reassessment of the indication for the precipitating medication, risk-reduction strategies for any necessary ongoing therapy, and appropriate referral when recurrent reactions, diagnostic uncertainty, or complex psychopharmacologic needs are present. This structured, collaborative approach reduces diagnostic delays, minimizes complications and repeat presentations, and improves both patient safety and overall satisfaction.